{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-093126","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2023-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.419232+00:00","generated_at":"2026-06-17T05:15:50.065913+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Mirum appoints Timothy Walbert to Board; Niall O'Donnell to resign at 2023 annual meeting","bullets":["Timothy Walbert appointed to Board as Class I director effective April 5, 2023.","Walbert receives option for 34,000 shares vesting over 3 years and $45,000 annual cash retainer.","Niall O'Donnell resigns as director and from Nominating and Corporate Governance Committee, effective at 2023 annual meeting, no dispute.","Walbert will serve until 2023 annual meeting and then be eligible for annual option grant of 17,000 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-093126","json":"https://secwatch.observer/filing/0001193125-23-093126.json","markdown":"https://secwatch.observer/filing/0001193125-23-093126.md","text":"https://secwatch.observer/filing/0001193125-23-093126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523093126/0001193125-23-093126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523093126/d462977d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:15:50.065913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6fd58159c2","claim":"Niall O'Donnell resigned as Director at Mirum Pharmaceuticals, Inc..","evidence_excerpt":"On April 5, 2023, Niall O’Donnell, Ph.D., notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of his resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, in each case, effective as of the date of the Company’s 2023 Annual Meeting of Stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523093126/0001193125-23-093126-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7c57cdb24b","claim":"Timothy Walbert was appointed as Director at Mirum Pharmaceuticals, Inc..","evidence_excerpt":"On April 5, 2023, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Timothy Walbert to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523093126/0001193125-23-093126-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}